Ticker

CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired employee.

Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) and Solid Biosciences (NASDAQ: SLDB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. Profitability This table compares Rapt Therapeutics and

Solid Biosciences maintains a 'Strong Buy' rating, driven by positive FDA alignment on the phase 3 IMPACT DUCHENNE trial for SGT-003 in DMD. The company expects key catalysts in mid-2026: potential FDA Accelerated Approval discussions for SGT-003 and additional data from the phase 1/2 INSPIRE DUCHENNE study. SLDB's capsid design targets improved muscle function and reduced toxicity, with phase 1/2 data showing 58%…

- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed…